{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03259867",
            "orgStudyIdInfo": {
                "id": "LT-004"
            },
            "organization": {
                "fullName": "Teclison Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Combination of TATE and PD-1 Inhibitor in Liver Cancer",
            "officialTitle": "Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody",
            "acronym": "TATE-PD1",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "combination-of-tate-and-pd-inhibitor-in-liver-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-09",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-08-16",
            "studyFirstSubmitQcDate": "2017-08-22",
            "studyFirstPostDateStruct": {
                "date": "2017-08-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-09-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Teclison Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.",
            "detailedDescription": "The goal of the study is to investigate whether tumor necrosis induced by Trans-arterial Tirapazamine Embolization (TATE) treatment can boost anti-tumor immunity and enhance the therapeutic efficacy of immune checkpoint inhibitor. Patients with advanced liver cancers (primary HCC or metastatic gastric cancer) who have progressed on a prior immune checkpoint inhibitor will be enrolled in the study. Liver lesions will be treated with up to 4 TATE treatments for optimal debulking, which also serve as a vaccination process toward tumor. Lesion not treated with TATE will be used for monitoring the response toward a PD-1 inhibitor (Nivolumab) for abscopal effect. If a patient subsequently develops an \"escape\" to the PD-1 inhibitor, patient can have another 2 TATE treatments of the escaped tumor lesion. Dosing of the PD-1 inhibitor is per standard FDA-approved dosing schedule and continues until progressive disease. The efficacy will be assessed by the response rate (RR) using RECIST."
        },
        "conditionsModule": {
            "conditions": [
                "Hepatocellular Carcinoma",
                "Gastric Cancer"
            ],
            "keywords": [
                "Hepatocellular carcinoma",
                "Immune checkpoint inhibitor",
                "Gastric cancer",
                "Progression"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "One arm for advanced HCC, and one for second line metastatic gastro-esophageal cancer . All enrolled patients will receive the same treatment with TATE and a PD-1 inhibitor (nivolumab) until disease progression",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 54,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Advanced Hepatocellular carcinoma",
                    "type": "EXPERIMENTAL",
                    "description": "PD-1 inhibitor (Nivolumab 360 mg Q3W IV ) starts at day 1, and continues until progression.\n\nTATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.",
                    "interventionNames": [
                        "Drug: Nivolumab Injectable Product",
                        "Combination Product: Trans-arterial tirapazamine embolization"
                    ]
                },
                {
                    "label": "Metastatic Gastro-esophageal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "PD-1 inhibitor (Nivolumab 360 mg Q3W IV) starts at day 1, and continues until progression.\n\nTATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization.",
                    "interventionNames": [
                        "Drug: Nivolumab Injectable Product",
                        "Combination Product: Trans-arterial tirapazamine embolization"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nivolumab Injectable Product",
                    "description": "a PD-1 immune check inhibitor",
                    "armGroupLabels": [
                        "Advanced Hepatocellular carcinoma",
                        "Metastatic Gastro-esophageal cancer"
                    ],
                    "otherNames": [
                        "OPDIVO"
                    ]
                },
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "Trans-arterial tirapazamine embolization",
                    "description": "Embolization with Lipiodol and Gelfoam",
                    "armGroupLabels": [
                        "Advanced Hepatocellular carcinoma",
                        "Metastatic Gastro-esophageal cancer"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Overall Response Rate",
                    "description": "Per RECIST 1.1 criteria",
                    "timeFrame": "up to 24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Duration of Response",
                    "description": "From the date of image-demonstrated response to the date of progression",
                    "timeFrame": "up to 24 months"
                },
                {
                    "measure": "Time to Progression",
                    "description": "From randomization to disease progression or death",
                    "timeFrame": "up to 24 months"
                },
                {
                    "measure": "Progression Free Survival",
                    "description": "From randomization to disease progression or death",
                    "timeFrame": "up to 24 months"
                },
                {
                    "measure": "Overall survival",
                    "description": "From randomization to death",
                    "timeFrame": "through study completion, an average of 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "1. Patients with a confirmed diagnosis of (1) advanced HCC or (2) metastatic gastric cancer.\n2. Patients between ages 18 and 80\n3. If HCC patients, they should have progressive disease (PD) on an immune therapy for advanced HCC. For patients with metastatic gastric cancer, they should have failed at least one line of systemic chemotherapy and an immune checkpoint inhibitor.\n4. Patients with liver tumor lesions with at least one with a diameter of 2 cm or bigger, which is amendable for (super-)selective TATE as the target lesion.\n5. ECOG score 2 or less\n6. Child-Pugh scores 5-7 for HCC patients\n7. All prior chemotherapy at least 4 weeks prior to study treatment. Immunotherapy not subject to this limitation.\n8. No major GI bleeding in the prior 2 months.\n\n8. Hgb\\>=8, platelet \\>= 50,000, Cr =\\< 2, AST and ALT \\< 10 X ULN, t-Bilirubin \\< 3, 9. Patients with a history of major autoimmune disorders excluded.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ray Lee, MD. PhD",
                    "role": "CONTACT",
                    "phone": "8043341076",
                    "email": "ray.lee01@teclison.com"
                },
                {
                    "name": "Chiwei Lu, PhD.",
                    "role": "CONTACT",
                    "email": "chiwei.lu4@teclison.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nadine Abi-Jaoudeh, MD",
                    "affiliation": "UC Irvine Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, Irvine",
                    "status": "RECRUITING",
                    "city": "Orange",
                    "state": "California",
                    "zip": "92868",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Miranda Duron",
                            "role": "CONTACT"
                        },
                        {
                            "role": "CONTACT",
                            "email": "mnduron@hs.uci.edu"
                        },
                        {
                            "name": "Nadine Abi-Jaoudeh, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.78779,
                        "lon": -117.85311
                    }
                },
                {
                    "facility": "University of Oklahoma Health Science Center",
                    "status": "RECRUITING",
                    "city": "Oklahoma City",
                    "state": "Oklahoma",
                    "zip": "73104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Melissa Yarbrough, RN",
                            "role": "CONTACT",
                            "email": "melissa-yarbrough@ouhsc.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.46756,
                        "lon": -97.51643
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Barbara Dion",
                            "role": "CONTACT",
                            "email": "badion@mcw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34041204",
                    "type": "BACKGROUND",
                    "citation": "Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK. Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021 May 17;8:421-434. doi: 10.2147/JHC.S304275. eCollection 2021."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006528",
                    "term": "Carcinoma, Hepatocellular"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                },
                {
                    "id": "D000008113",
                    "term": "Liver Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000000230",
                    "term": "Adenocarcinoma"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20559",
                    "name": "Disease Progression",
                    "relevance": "LOW"
                },
                {
                    "id": "M9613",
                    "name": "Carcinoma, Hepatocellular",
                    "asFound": "Hepatocellular Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11113",
                    "name": "Liver Neoplasms",
                    "asFound": "Liver Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "D000077704",
                    "term": "Tirapazamine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M8146",
                    "name": "Ethiodized Oil",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M8896",
                    "name": "Gelatin Sponge, Absorbable",
                    "relevance": "LOW"
                },
                {
                    "id": "M1875",
                    "name": "Tirapazamine",
                    "asFound": "Prior Chemotherapy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Coag",
                    "name": "Coagulants"
                }
            ]
        }
    },
    "hasResults": false
}